Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H24N2O |
Molecular Weight | 248.3639 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCCN3CCC[C@]([H])([C@@]4([H])CCCC(=O)N4C1)[C@]23[H]
InChI
InChIKey=ZSBXGIUJOOQZMP-BHPKHCPMSA-N
InChI=1S/C15H24N2O/c18-14-7-1-6-13-12-5-3-9-16-8-2-4-11(15(12)16)10-17(13)14/h11-13,15H,1-10H2/t11-,12-,13-,15+/m1/s1
Molecular Formula | C15H24N2O |
Molecular Weight | 248.3639 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Sophoridine is a quinolizidine alkaloid isolated from traditional Chinese herbs, which exists in the stems and leafs of Leguminous plant Sophora alopecuroides L., Euchresta japonica Benth., and the roots of Sophora alopecuroides Ait. Sophoridine-induced synchronous oscillations in the hippocampus could elicit the generation and development of seizure. Accumulating evidence demonstrates remarkable pharmacological effects of Sophoridine, including anti-inflammatory, anti-virus and anti-cancer effects. Sophoridine is promising to be a novel, potent and selective antitumor drug candidate for pancreatic cancer. It was shown that sophoridine is able to suppress hepatocellular carcinoma in vitro and vivo. Sophoridine dose- and time-dependently blocks the RANKL-induced osteoclasts formation and the activation of ERK and c-Fos as well as the induction and nucleus translocation of NFATc1.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: RANKL-ERK-NFAT pathway Sources: https://www.ncbi.nlm.nih.gov/pubmed/29058425 |
|||
Target ID: WP254 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28893319 |
|||
Target ID: PTEN/PI3K/AKT, Caspase-3/-9 and MMP-2/-9 signaling pathway Sources: https://www.ncbi.nlm.nih.gov/pubmed/28858730 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29058425
Mice: 15 mg/kg body weight. The daily administration continued for 28 days.
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28893319
Eleven human cancer cell lines and 8 normal cell lines were exposed to various concentrations of Sophoridine (0–500 uM/L) for 48 h. Cell viability was determined by the CCK-8 assay. Sophoridine exhibited remarkable inhibition effects to the growth of human pancreatic, gastric, liver, colon, gallbladder, and prostate carcinoma
cells with IC50 values of about 20 uM/L to 200 uM/L.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:30:18 GMT 2023
by
admin
on
Sat Dec 16 09:30:18 GMT 2023
|
Record UNII |
W5S1M800J7
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6882-68-4
Created by
admin on Sat Dec 16 09:30:18 GMT 2023 , Edited by admin on Sat Dec 16 09:30:18 GMT 2023
|
PRIMARY | |||
|
W5S1M800J7
Created by
admin on Sat Dec 16 09:30:18 GMT 2023 , Edited by admin on Sat Dec 16 09:30:18 GMT 2023
|
PRIMARY | |||
|
DTXSID60218927
Created by
admin on Sat Dec 16 09:30:18 GMT 2023 , Edited by admin on Sat Dec 16 09:30:18 GMT 2023
|
PRIMARY | |||
|
165549
Created by
admin on Sat Dec 16 09:30:18 GMT 2023 , Edited by admin on Sat Dec 16 09:30:18 GMT 2023
|
PRIMARY |